Guopan Yu

1.3k total citations
69 papers, 763 citations indexed

About

Guopan Yu is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Guopan Yu has authored 69 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 27 papers in Molecular Biology and 19 papers in Genetics. Recurrent topics in Guopan Yu's work include Acute Myeloid Leukemia Research (43 papers), Hematopoietic Stem Cell Transplantation (16 papers) and Histone Deacetylase Inhibitors Research (14 papers). Guopan Yu is often cited by papers focused on Acute Myeloid Leukemia Research (43 papers), Hematopoietic Stem Cell Transplantation (16 papers) and Histone Deacetylase Inhibitors Research (14 papers). Guopan Yu collaborates with scholars based in China, United States and Myanmar. Guopan Yu's co-authors include Qifa Liu, Jing Sun, Fen Huang, Zhiping Fan, Hongsheng Zhou, Fan‐Yi Meng, Changxin Yin, Li Xuan, Yu Zhang and Ling Jiang and has published in prestigious journals such as Nature Communications, Blood and Nature Cell Biology.

In The Last Decade

Guopan Yu

64 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guopan Yu China	14	428	214	199	130	100	69	763
Marta S. Gallego Argentina	15	317 0.7×	228 1.1×	98 0.5×	82 0.6×	257 2.6×	43	644
Jonathan Canaani Israel	19	669 1.6×	262 1.2×	131 0.7×	198 1.5×	261 2.6×	65	978
Shyamala Navada United States	11	259 0.6×	252 1.2×	118 0.6×	140 1.1×	35 0.3×	49	574
Lingyun Wu China	18	571 1.3×	441 2.1×	186 0.9×	137 1.1×	60 0.6×	62	971
Dimitrios Margaritis Greece	11	246 0.6×	147 0.7×	138 0.7×	80 0.6×	26 0.3×	36	598
Μαρία Σαμαρά Greece	13	154 0.4×	155 0.7×	183 0.9×	74 0.6×	13 0.1×	37	544
Birol Güvenç Türkiye	13	169 0.4×	105 0.5×	173 0.9×	43 0.3×	19 0.2×	57	445
Jamil Dierov United States	11	182 0.4×	412 1.9×	115 0.6×	161 1.2×	49 0.5×	15	733
Gabriel M. Pagnotti United States	15	72 0.2×	374 1.7×	113 0.6×	233 1.8×	29 0.3×	29	939
Natalie V. Singer United States	10	165 0.4×	251 1.2×	51 0.3×	154 1.2×	19 0.2×	18	798

Countries citing papers authored by Guopan Yu

Since Specialization

Citations

This map shows the geographic impact of Guopan Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guopan Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guopan Yu more than expected).

Fields of papers citing papers by Guopan Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guopan Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guopan Yu. The network helps show where Guopan Yu may publish in the future.

Co-authorship network of co-authors of Guopan Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Guopan Yu. A scholar is included among the top collaborators of Guopan Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guopan Yu. Guopan Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Xuejie, Hongsheng Zhou, Pengcheng Shi, et al.. (2025). Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia. Therapeutic Advances in Hematology. 16. 1584237363–1584237363. 2 indexed citations

Liu, Qifa, Na Xu, Fen Huang, et al.. (2025). Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial. The Lancet Regional Health - Western Pacific. 61. 101664–101664. 1 indexed citations

Wang, Liang, Shu‐Heng Jiang, Pei Chen, et al.. (2025). 151P: Real-world adjuvant treatment patterns in Chinese patients with resected stages I to III EGFR-mutated NSCLC: A multicenter observational study (ADDRESS, CATO-2001). Journal of Thoracic Oncology. 20(3). S107–S108.

Yu, Guopan, Xiaofan Chen, Weixiang Lu, et al.. (2024). Decreasing circ_0014614 promotes the differentiation of bone marrow flineage cells into megakaryocytes in essential thrombocythemia via activiation of miR-138-5p/caspase3 axis. Blood Cells Molecules and Diseases. 107. 102855–102855. 1 indexed citations

Shi, Rongyi, Neng Zhou, Xuan Li, et al.. (2024). Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. Nature Cell Biology. 26(8). 1346–1358. 4 indexed citations

Yu, Guopan, et al.. (2024). The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases. Leukemia & lymphoma. 65(11). 1659–1674. 2 indexed citations

Jia, Xi, Sijian Yu, Huan Li, et al.. (2024). Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission. Cancer Medicine. 13(4). e7074–e7074. 2 indexed citations

Zhang, Yu, Xin Du, Dongjun Lin, et al.. (2024). Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 150(7). 336–336. 2 indexed citations

Yu, Guopan, Yu Zhang, Hua Jin, et al.. (2023). Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study. Blood. 142(Supplement 1). 4262–4262.

10.

Yu, Guopan, et al.. (2023). The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia. Blood. 142(Supplement 1). 5909–5909. 1 indexed citations

11.

Cai, Liangliang, Xiao‐Jun Wei, Xiaoxiao Guo, et al.. (2023). [A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in patients with hematological malignancies].. PubMed. 44(6). 479–483. 3 indexed citations

12.

Zhang, Yu, Guopan Yu, Zhiqiang Sun, et al.. (2023). Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study. Annals of Hematology. 102(12). 3369–3381. 1 indexed citations

13.

Lu, Weixiang, Guopan Yu, Yanlin Li, et al.. (2023). Identifying prognostic biomarker related to immune infiltration in acute myeloid leukemia. Clinical and Experimental Medicine. 23(8). 4553–4562.

14.

Chen, Yishan, Ying Yang, Qiang Wang, et al.. (2022). Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation. Journal of Translational Medicine. 20(1). 300–300. 8 indexed citations

15.

Jiang, Xuejie, Ling Jiang, Fang Chen, et al.. (2021). Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. Journal of Translational Medicine. 19(1). 117–117. 9 indexed citations

16.

Yin, Changxin, Ling Jiang, Qiang Wang, et al.. (2019). Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. Bone Marrow Transplantation. 55(4). 740–748. 23 indexed citations

17.

Jiang, Xuejie, Changxin Yin, Ling Jiang, et al.. (2017). Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia. Blood. 130. 5089–5089. 1 indexed citations

18.

Yu, Guopan, Changxin Yin, Ling Jiang, et al.. (2016). Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway. Oncology Reports. 36(3). 1626–1632. 13 indexed citations

19.

Liu, Hui, Xiao Zhai, Jing Sun, et al.. (2013). Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. Journal of Hematology & Oncology. 6(1). 15–15. 70 indexed citations

20.

Jiang, Ling, Guopan Yu, Wei Meng, et al.. (2012). Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biology. 34(2). 629–636. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact